Drug Trial Radar · NCT05696626
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 31, 2023
Primary completion
Apr 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- LeonaBioIndustry
- Sponsor type
- Industry
- First posted
- Jan 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Conditions
- Metastatic Breast Cancer
Interventions
Lasofoxifene in combination with abemaciclibDrug
5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
Fulvestrant in combination with abemaciclibDrug
Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: Within approximately 3 years
Locations
224 sites in 17 countries. Site status is shown where the registry gives one.
Mayo Clinic - Scottsdale
Scottsdale, Arizona · Recruiting
University of Arizona - Cancer Center
Tucson, Arizona · Recruiting
Providence Medical Foundation - Santa Rosa, CA
Santa Rosa, California · Recruiting
Mayo Clinic - Jacksonville
Jacksonville, Florida · Recruiting
Miami Cancer Institute
Miami, Florida · Recruiting
Miami Cancer Institute Plantation
Plantation, Florida · Recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Completed
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan · Recruiting
Allina Health System DBA Virginia Piper Cancer Institute
Minneapolis, Minnesota · Completed
Mayo Clinic - Rochester
Rochester, Minnesota · Recruiting
Saint Luke's Cancer Institute
Kansas City, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Renown Regional Medical Centre
Reno, Nevada · Recruiting
Cancer Care Specialists
Reno, Nevada · Recruiting
New Jersey Cancer Care, PA
Belleville, New Jersey · Withdrawn
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Presbyterian Kaseman Hospital
Albuquerque, New Mexico · Not yet recruiting
Presbyterian Rust Cancer Center
Rio Rancho, New Mexico · Recruiting
The Blavatnik Family - Chelsea Medical Center at Mount Sinai
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Altru Health Systems
Grand Forks, North Dakota · Completed
University Hospitals Seidman Cancer Center
Cleveland, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Withdrawn
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
Columbus, Ohio · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Completed
Baylor College of Medicine
Houston, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Harris Health System - Smith Clinic
Houston, Texas · Recruiting
Swedish Cancer Institute (SCI)
Seattle, Washington · Withdrawn
Blacktown Hospital
Blacktown, Australia · Recruiting
Concord Repatriation General Hospital
Concord, Australia · Recruiting
Mater Misericordiae Ltd, South Brisbane
South Brisbane, Australia · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
Showing 40 of 224 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.